Organon has entered a commercialization partnership with Daiichi Sankyo Europe to market the bempedoic acid drug Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway. Under the agreement, Organon will handle distribution and promotion while Daiichi Sankyo Europe retains the marketing authorization, allowing the company to leverage its established commercial network to accelerate market entry for a first‑in‑class lipid‑lowering therapy.
The deal represents a strategic pivot for Organon, which has historically focused on women’s health and biosimilars. By adding Nilemdo®—a drug that offers an alternative for patients who cannot tolerate statins—Organon broadens its therapeutic reach and creates a new revenue stream for its General Medicines segment. In 2024 the company generated $6.4 billion in revenue, up 3 % at constant currency, and reported a 30.6 % adjusted EBITDA margin. Guidance for 2025 projects revenue of $6.125–$6.325 billion, indicating a slight decline that the Nilemdo® partnership could help offset.
Statin intolerance affects roughly 6–10 % of patients worldwide, and women are about 47 % more likely to experience intolerance. The six European markets covered by the deal represent a sizable addressable population of statin‑intolerant patients, many of whom currently rely on less effective therapies such as ezetimibe or are managed with lifestyle changes alone. Nilemdo® works by inhibiting ATP citrate lyase, an upstream enzyme in cholesterol biosynthesis, and has shown robust LDL‑lowering efficacy in clinical trials, positioning it favorably against existing options.
Organon’s CEO Kevin Ali highlighted the partnership as a “strategic fit that reinforces our mission to deliver impactful treatments for a healthier everyday life.” The collaboration also aligns with the company’s broader focus on women’s health, as statin intolerance disproportionately affects women. While the agreement’s financial terms are not disclosed, the partnership is expected to contribute a meaningful portion of revenue to the General Medicines segment and support Organon’s goal of maintaining a 31 % adjusted EBITDA margin in 2025.
The deal underscores Organon’s intent to diversify beyond its core product lines and to capitalize on unmet needs in cardiovascular care. By partnering with a specialist in cardiovascular innovation, Organon can accelerate market penetration and strengthen its competitive position in a sector where first‑in‑class therapies are highly valued.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.